

PRODUCT MONOGRAPH  
INCLUDING PATIENT MEDICATION INFORMATION

<sup>Pr</sup>ARICEPT®  
(donepezil hydrochloride)  
Tablets 5 and 10 mg, oral administration

Cholinesterase Inhibitor

Pfizer Canada ULC  
17300 Trans-Canada Highway  
Kirkland, Québec  
H9J 2M5  
[www.pfizer.ca](http://www.pfizer.ca)

Date of Initial Authorization:  
AUG 12, 1997

Date of Revision:  
DEC 05, 2024

Submission Control Number: 288646

® ARICEPT is a registered trademark of Eisai Co. Ltd., Tokyo, Japan/used under license

**RECENT MAJOR LABEL CHANGES**

<a href="#">1 INDICATION, 1.1 Pediatrics</a>	2024-09
<a href="#">1 INDICATION, 1.2 Geriatrics</a>	2024-09
<a href="#">2 CONTRAINDICATIONS</a>	2024-09
<a href="#">4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations</a>	2024-09
<a href="#">4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment</a>	2024-09
<a href="#">4 DOSAGE AND ADMINISTRATION, 4.4 Administration</a>	2024-09
<a href="#">4 DOSAGE AND ADMINISTRATION, 4.5 Missed Dose</a>	2024-09
<a href="#">7 WARNINGS AND PRECAUTIONS, Cardiovascular</a>	2024-09

**TABLE OF CONTENTS**

Sections or subsections that are not applicable at the time of the most recent authorized product monograph are not listed.

**RECENT MAJOR LABEL CHANGES ..... 2**

**TABLE OF CONTENTS ..... 2**

**PART I: HEALTH PROFESSIONAL INFORMATION ..... 4**

**1 INDICATIONS..... 4**

    1.1 Pediatrics..... 4

    1.2 Geriatrics..... 4

**2 CONTRAINDICATIONS..... 4**

**4 DOSAGE AND ADMINISTRATION..... 4**

    4.1 Dosing Considerations ..... 4

    4.2 Recommended Dose and Dosage Adjustment ..... 5

    4.4 Administration ..... 5

    4.5 Missed Dose ..... 5

**5 OVERDOSAGE..... 6**

**6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ..... 6**

**7 WARNINGS AND PRECAUTIONS..... 7**

    7.1 Special Populations ..... 9

        7.1.1 Pregnant Women ..... 9

        7.1.2 Breast-feeding..... 9

7.1.3	Pediatrics.....	9
7.1.4	Geriatrics.....	10
<b>8</b>	<b>ADVERSE REACTIONS.....</b>	<b>11</b>
8.1	Adverse Reaction Overview .....	11
8.2	Clinical Trial Adverse Reactions .....	11
8.3	Less Common Clinical Trial Adverse Reactions.....	17
8.4	Abnormal Laboratory Findings: Hematology, Clinical Chemistry and Other Quantitative Data.....	18
8.5	Post-Market Adverse Reactions.....	19
<b>9</b>	<b>DRUG INTERACTIONS .....</b>	<b>19</b>
9.2	Drug Interactions Overview .....	19
9.4	Drug-Drug Interactions .....	19
9.5	Drug-Food Interactions.....	20
9.6	Drug-Herb Interactions.....	20
9.7	Drug-Laboratory Test Interactions.....	20
<b>10</b>	<b>CLINICAL PHARMACOLOGY.....</b>	<b>20</b>
10.1	Mechanism of Action .....	20
10.3	Pharmacokinetics.....	21
<b>11</b>	<b>STORAGE, STABILITY AND DISPOSAL.....</b>	<b>22</b>
<b>PART II: SCIENTIFIC INFORMATION .....</b>		<b>23</b>
<b>13</b>	<b>PHARMACEUTICAL INFORMATION .....</b>	<b>23</b>
<b>14</b>	<b>CLINICAL TRIALS .....</b>	<b>24</b>
14.1	Clinical Trials by Indication .....	24
<b>15</b>	<b>MICROBIOLOGY .....</b>	<b>31</b>
<b>16</b>	<b>NON-CLINICAL TOXICOLOGY .....</b>	<b>31</b>
	General Toxicology: .....	31
	Special Toxicology .....	41
<b>PATIENT MEDICATION INFORMATION .....</b>		<b>43</b>

## PART I: HEALTH PROFESSIONAL INFORMATION

### 1 INDICATIONS

ARICEPT (donepezil hydrochloride) is indicated for:

- symptomatic treatment of patients with mild, moderate and severe dementia of the Alzheimer's type.

Efficacy of ARICEPT in patients with mild to moderate Alzheimer's disease was established in two 24 week and one 54-week placebo-controlled trials. Efficacy in patients with severe Alzheimer's disease was established in three 24-week/6-month placebo-controlled trials.

ARICEPT tablets should only be prescribed by (or following consultation with) clinicians who are experienced in the diagnosis and management of Alzheimer's disease.

#### 1.1 Pediatrics

Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see [7.1.3 Pediatrics](#)).

#### 1.2 Geriatrics

Geriatrics (≥ 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. Dose escalation in patients > 85 years old should proceed with caution (see [4.1 Dosing Considerations](#); and [7.1.4 Geriatrics](#)).

### 2 CONTRAINDICATIONS

ARICEPT (donepezil hydrochloride) is contraindicated in:

- patients with known hypersensitivity to donepezil hydrochloride, to piperidine derivatives, or to any ingredient in the formulation, including any non-medicinal ingredients, or component of the container. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).
- patients with history of QT prolongation and/or torsade de pointes, including congenital long QT syndromes, history of cardiac arrhythmias (see [7 WARNINGS AND PRECAUTIONS, Cardiovascular](#), and [9.2 Drug Interactions Overview](#)).

### 4 DOSAGE AND ADMINISTRATION

#### 4.1 Dosing Considerations

ARICEPT (donepezil hydrochloride) should only be prescribed by (or following consultation with) clinicians who are experienced in the diagnosis and management of Alzheimer's disease.

### **Special Populations:**

The use of ARICEPT in Alzheimer's disease patients with chronic illnesses common among the geriatric population, should be considered only after careful risk/benefit assessment and include close monitoring for adverse events. It is recommended that ARICEPT be used with caution in these patient populations (see [7 WARNINGS AND PRECAUTIONS](#)). Adverse events are more common in individuals of low body weight, in patients  $\geq$  85 years old and in females.

In elderly women of low body weight, the dose should not exceed 5 mg/day.

In a population of cognitively impaired individuals, safe use of this and all other medications may require supervision.

### **Patients with renal and hepatic impairment:**

A similar dose schedule can be followed for patients with renal impairment, as clearance of donepezil hydrochloride is not affected by this condition.

Due to possible increased exposure in mild to moderate hepatic impairment, dose escalation should be performed according to individual tolerability (see [10.3 Pharmacokinetics](#)). There are no data for patients with severe hepatic impairment.

## **4.2 Recommended Dose and Dosage Adjustment**

**Adults:** The recommended initial dose of ARICEPT is 5 mg taken once daily. Therapy with the 5 mg dose should be maintained for 4-6 weeks before considering a dose increase, in order to avoid or decrease the incidence of the most common adverse reactions to the drug (see [8 ADVERSE REACTIONS](#)) and to allow plasma levels to reach steady state. Based on clinical judgement, the 10 mg daily dose may be considered following 4-6 weeks of treatment at 5 mg/day. The maximum recommended dose is 10 mg taken once daily.

Following initiation of therapy or any dosage increase, patients should be closely monitored for adverse effects.

Health Canada has not authorized an indication for pediatric use (see [7.1.3 Pediatrics](#)).

## **4.4 Administration**

ARICEPT should be taken once daily in the morning or evening. It may be taken with or without food.

ARICEPT tablets should be swallowed whole with water.

In case of sleep disturbances including abnormal dreams, nightmares or insomnia (see [8 ADVERSE REACTIONS](#)) intake of ARICEPT in the morning may be considered.

## **4.5 Missed Dose**

The missed dose should be taken at the next scheduled dose. Doses should not be doubled. If therapy has been interrupted for several days or longer, the patient should be restarted at the lowest dose and the dose escalated to the current dose.

## 5 OVERDOSAGE

**Symptoms:** Overdosage with cholinesterase inhibitors can result in cholinergic crisis characterized by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved.

**Treatment:** The elimination half-life of ARICEPT (donepezil hydrochloride) at recommended doses is approximately 70 hours, thus, in the case of overdose, it is anticipated that prolonged treatment and monitoring of adverse and toxic reactions will be necessary. As in any case of overdose, general supportive measures should be utilized.

Tertiary anticholinergics such as atropine may be used as an antidote for ARICEPT overdose. Intravenous atropine sulfate titrated to effect is recommended: an initial dose of 1.0 to 2.0 mg IV with subsequent doses based upon clinical response. Atypical responses in blood pressure and heart rate have been reported with other cholinomimetics when co-administered with quaternary anticholinergics such as glycopyrrolate. It is not known whether ARICEPT and/or its metabolites can be removed by dialysis (hemodialysis, peritoneal dialysis, or hemofiltration).

Dose-related signs of toxicity observed in animals included reduced spontaneous movement, prone position, staggering gait, lacrimation, clonic convulsions, depressed respiration, salivation, miosis, fasciculation, and lower body surface temperature.

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669)

## 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

**Table 1 – Dosage Forms, Strengths, Composition and Packaging**

Route of Administration	Dosage Form / Strength/Composition	Non-Medicinal Ingredients
oral	Tablets 5 mg and 10 mg	Corn starch, hydroxypropylcellulose, lactose monohydrate, microcrystalline cellulose, and magnesium stearate.  The film coating contains Hypromellose, polyethylene glycol, talc and titanium dioxide. Additionally, the 10 mg tablet contains iron oxide as a coloring agent.

### Description

ARICEPT (donepezil hydrochloride) is supplied as film-coated tablets containing 5 mg (white tablets) or 10 mg (yellow tablets) of donepezil hydrochloride. The name ARICEPT and the strength are debossed on each tablet.

Each 5 and 10 mg, film-coated tablet contains 5 and 10 mg of donepezil hydrochloride respectively, equivalent to 4.56 and 9.12 mg of donepezil free base.

ARICEPT is available in high-density polyethylene (HDPE) bottles of 30 tablets.

## 7 WARNINGS AND PRECAUTIONS

### General

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine (see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#)).

### Carcinogenesis and Mutagenesis

Refer to [16 NON-CLINICAL TOXICOLOGY, Carcinogenicity](#) for discussion on animal data.

### Cardiovascular

Because of their pharmacological action, cholinesterase inhibitors may have vagotonic effects on heart rate (e.g., bradycardia). The potential for this action may be particularly important to patients with "sick sinus syndrome" or other supraventricular cardiac conduction conditions.

In clinical trials in Alzheimer's disease, most patients with serious cardiovascular conditions were excluded. Patients such as those with controlled hypertension (DBP < 95 mmHg), right bundle branch blockage, and pacemakers were included. Therefore, caution should be taken in treating patients with active coronary artery disease and congestive heart failure. Syncopal episodes have been reported in association with the use of ARICEPT. It is recommended that ARICEPT should not be used in patients with cardiac conduction abnormalities (except for right bundle branch block) including "sick sinus syndrome" and those with unexplained syncopal episodes.

There have been post-marketing reports of QTc prolongation and torsade de pointes in patients using donepezil. Donepezil hydrochloride should therefore be used with caution in patients with pre-existing or family history of QTc prolongation, in patients treated with drugs affecting the QTc interval, or in patients with relevant pre-existing cardiac disease (e.g. uncompensated heart failure, recent myocardial infarction, bradyarrhythmias), or electrolyte disturbances (e.g., hypokalaemia, hypomagnesaemia). Clinical monitoring (ECG) may be required (see [2 CONTRAINDICATIONS](#)).

### Dependence, Tolerance and/or Abuse Liability

In male rats, there were no significant drug dependence liability as assessed by the primary dependence test, donepezil hydrochloride substitution test and naloxone test (see [16 NON-CLINICAL TOXICOLOGY, Special Toxicology](#)).

### Driving and Operating Machinery

Alzheimer's disease may cause gradual impairment of driving performance or compromise the ability to use machinery. Furthermore, donepezil can induce fatigue, dizziness and muscle cramps, mainly when initiating or increasing the dose. While taking ARICEPT, patients should routinely be evaluated for their ability to continue driving or operating complex machines.

### Gastrointestinal

Through their primary action, cholinesterase inhibitors may be expected to increase gastric acid secretion due to increased cholinergic activity. Therefore, patients at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) including high doses of acetylsalicylic acid (ASA), should be monitored for symptoms of active

or occult gastrointestinal bleeding. Clinical studies of ARICEPT have shown no increase, relative to placebo in the incidence of either peptic ulcer disease or gastrointestinal bleeding (see [8 ADVERSE REACTIONS](#)).

ARICEPT, as a predictable consequence of its pharmacological properties, has been shown to produce, in controlled clinical trials in patients with Alzheimer's disease, diarrhea, nausea and vomiting. These effects, when they occur, appear more frequently with the 10 mg dose than with the 5 mg dose. In most cases, these effects have usually been mild and transient, sometimes lasting 1 to 3 weeks and have resolved during continued use of ARICEPT (see [8 ADVERSE REACTIONS](#)). Treatment with the 5 mg/day dose for 4-6 weeks prior to increasing the dose to 10 mg/day is associated with a lower incidence of gastrointestinal intolerance.

### **Genitourinary**

Although not observed in clinical trials of ARICEPT, cholinomimetics may cause bladder outflow obstruction.

### **Hepatic/Biliary/Pancreatic**

There is limited information regarding the pharmacokinetics of ARICEPT in hepatically impaired Alzheimer disease patients (see [10.3 Pharmacokinetics](#)).

Close monitoring for adverse effects in patients with hepatic disease being treated with ARICEPT is therefore recommended.

### **Musculoskeletal**

Rare cases of rhabdomyolysis (including acute renal failure) have been reported in patients treated with ARICEPT, particularly in the days following dose initiation and dose increase. Majority of these cases occurred independently of the occurrence of Neuroleptic Malignant Syndrome (NMS).

Patients should be carefully monitored for muscle pain, tenderness or weakness and darkened urine, particularly if accompanied by malaise or fever. Blood creatine phosphokinase (CPK) levels should be assessed in patients experiencing these symptoms. ARICEPT therapy should be discontinued if markedly elevated CPK levels are measured and/or if the patient develops signs and symptoms indicative of rhabdomyolysis. Although the decision to discontinue ARICEPT should be made based on the clinical judgement of the treating physician, in most post-marketing cases, therapy was withdrawn when CPK levels were 5X upper limit of normal or higher. Caution should be particularly exercised in prescribing ARICEPT to patients with predisposing/risk factors such as prior history of muscular disorders, uncontrolled hypothyroidism, hepatic or renal impairment, and in patients who are receiving concomitant medications that can cause rhabdomyolysis (e.g., statins, antipsychotics, selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor).

### **Neurologic**

**Neuroleptic Malignant Syndrome (NMS):** There have been very rare post-marketing reports of Neuroleptic Malignant Syndrome (NMS) in patients treated with ARICEPT with or without concomitant antipsychotic medication. NMS is a potentially life-threatening condition characterized by hyperthermia, muscle rigidity, autonomic instability (e.g., irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia), altered consciousness and elevated serum creatine phosphokinase (CPK) levels. Additional signs may include myoglobinuria (rhabdomyolysis) and acute renal failure. If a patient develops signs and symptoms indicative of NMS or presents with unexplained high fever in the absence of additional clinical manifestations of NMS, ARICEPT therapy should be discontinued.



**Seizures:** Some cases of seizures have been reported with the use of ARICEPT in clinical trials and from spontaneous adverse reaction reporting. Cholinomimetics can cause a reduction of seizure threshold, increasing the risk of seizures. However, seizure activity may also be a manifestation of Alzheimer's disease. The risk/benefit of ARICEPT treatment for patients with a history of seizure disorder must therefore be carefully evaluated.

ARICEPT has not been studied in patients with Parkinsonian features. The efficacy and safety of **ARICEPT** in these patients are unknown.

### **Peri-Operative Considerations**

**Anesthesia:** ARICEPT, as a cholinesterase inhibitor, is likely to exaggerate succinylcholine-type muscle relaxation during anesthesia.

### **Renal**

There is limited information regarding the pharmacokinetics of ARICEPT in renally impaired Alzheimer disease patients (see [10.3 Pharmacokinetics](#)).

Close monitoring for adverse effects in patients with renal disease being treated with ARICEPT is therefore recommended.

### **Respiratory**

Because of their cholinomimetic action, cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease. ARICEPT has not been studied in patients under treatment for these conditions and should therefore be used with particular caution in such patients.

### **Reproductive Health**

**Fertility:** There is no information available on the effects of donepezil hydrochloride on human fertility.

## **7.1 Special Populations**

### **7.1.1 Pregnant Women**

The safety of ARICEPT during pregnancy has not been established and therefore, it should not be used in women of childbearing potential unless, in the opinion of the physician, the potential benefits to the patient outweigh the possible hazards to the fetus. Teratology studies conducted in pregnant rats at doses of up to 16 mg/kg/day and in pregnant rabbits at doses of up to 10 mg/kg/day did not disclose any evidence for a teratogenic potential of ARICEPT (see [16 NON-CLINICAL TOXICOLOGY](#)).

### **7.1.2 Breast-feeding**

The safety of ARICEPT during lactation has not been established.

It is unknown if ARICEPT is excreted in human milk, and therefore Aricept should not be used in nursing mothers.

### **7.1.3 Pediatrics**

**Pediatrics (< 18 years of age):** No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

There are no adequate and well-controlled trials to document the safety and efficacy of ARICEPT in any illness occurring in children. Therefore, ARICEPT is not recommended for use in children.

#### 7.1.4 Geriatrics

**Geriatrics (≥ 65 years of age):** In controlled clinical studies with 5 and 10 mg ARICEPT in patients with mild to moderate Alzheimer's disease, there were 536 patients between the ages of 65 to 84, and 37 patients aged 85 years or older treated with ARICEPT. In controlled clinical trials of patients with severe Alzheimer's disease there were 158 patients who were 74 years of age or less, 276 patients between the ages of 75 and 84, and 139 patients aged 85 years or older treated with ARICEPT. In Alzheimer's disease patients, nausea, diarrhea, vomiting, insomnia, fatigue and anorexia increased with dose and age, and the incidence appeared to be greater in female patients. Since cholinesterase inhibitors as well as Alzheimer's disease can be associated with significant weight loss, caution is advised regarding the use of ARICEPT in low body weight elderly patients, especially in those ≥85 years old (see [4.1 Dosing Considerations, Special Populations](#)).

**Use in Elderly Patients with Comorbid Disease:** There is limited safety information for ARICEPT in patients with mild to moderate or severe Alzheimer's disease and significant comorbidity. The use of ARICEPT in Alzheimer's disease patients with chronic illnesses common among the geriatric population, should be considered only after careful risk/benefit assessment and include close monitoring for adverse events. Caution is advised regarding the use of ARICEPT doses above 5 mg in this patient population.

In severe Alzheimer's disease, the possibility of comorbid vascular disease and risk factors for vascular adverse events and mortality should be considered.

#### **Patients with vascular dementia:**

Three clinical trials, each of 6 months duration, were conducted to evaluate the safety and efficacy of ARICEPT for the symptomatic treatment of individuals meeting the NINDS-AIREN criteria for probable or possible vascular dementia. The NINDS-AIREN criteria are designed to identify patients with dementia that appears to be due solely to vascular causes, and to exclude patients with Alzheimer's disease. ARICEPT was not shown to be an effective treatment for patients with vascular dementia in two of these clinical trials.

The safety profile from these controlled clinical trials in vascular dementia patients indicates that the rate of occurrence of treatment emergent adverse events overall was higher in vascular dementia patients (86%) than in Alzheimer's disease patients (75%). This was seen in both ARICEPT-treated subjects and placebo-treated subjects and may relate to the greater number of co-morbid medical conditions in the vascular dementia population.

In two of the clinical trials there was a higher rate of mortality among patients treated with ARICEPT, during double-blind treatment; this result was statistically significant for one of these two trials. For the three vascular dementia studies combined, the mortality rate in the ARICEPT group (1.7%, 25/1475) was numerically higher than in the placebo group (1.1%, 8/718), but this difference was not statistically significant.

These results are summarized as follows:

**Table 2 Mortality rates in ARICEPT vascular dementia clinical trials**

Study	Placebo	ARICEPT 5 mg	p-value <sup>x</sup>	ARICEPT 10 mg	p-value <sup>x</sup>
307	3.5% (7/199)	1.0% (2/198)	0.17	2.4% (5/206)	0.57
308	0.5% (1/193)	1.9% (4/208)	0.37	1.4% (3/215)	0.62
319	0% (0/326)	1.7% (11/648)	0.02	*	NA
Combined	1.1% (8/718)	1.7% (25/1475)			0.35

\* No 10 mg ARICEPT treatment arm in Study 319

<sup>x</sup> p-values are for 5 mg donepezil vs placebo and 10 mg donepezil vs placebo

The majority of deaths in patients taking either ARICEPT or placebo appear to have resulted from various vascular related causes, which may be expected in this elderly, fragile, population with co-morbid vascular disease. In the three combined vascular dementia clinical trials there were similar proportions of patients with serious AEs in both treatment groups (approximately 15%), and similar proportions of patients with serious cardiovascular or cerebrovascular adverse events (non-fatal and fatal, approximately 8%). The proportion of patients who had a fatal cardiovascular or cerebrovascular adverse event was numerically higher in the ARICEPT group than in the placebo group, but this difference was not statistically significant across the three trials.

There is no evidence of an increased risk of mortality when ARICEPT is used in patients with mild to moderate Alzheimer's disease.

## 8 ADVERSE REACTIONS

### 8.1 Adverse Reaction Overview

The most common adverse events, defined as those occurring at a frequency of at least 5% in patients receiving 10 mg/day and twice the placebo rate, are largely predicted by ARICEPT's cholinomimetic effects. These include nausea, diarrhea, insomnia, vomiting, muscle cramp, fatigue and anorexia, in mild to moderate Alzheimer's Disease, and vomiting, diarrhea, nausea, and aggression, in severe Alzheimer's Disease.

These adverse events were often of mild intensity and transient, resolving during continued ARICEPT treatment without the need for dose modification.

### 8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

#### ***Mild to Moderate Alzheimer's Disease***

A total of 747 patients with mild to moderate Alzheimer's disease were treated in controlled clinical studies with ARICEPT (donepezil hydrochloride). Of these patients, 613 (82%) completed the studies. The mean duration of treatment for all ARICEPT groups was 132 days (range 1-356 days).

**Adverse Events Leading to Discontinuation:** The rates of discontinuation from controlled clinical trials

of ARICEPT due to adverse events for the ARICEPT 5 mg/day treatment groups were comparable to those of placebo-treatment groups at approximately 5%. The rate of discontinuation of patients who received the 10 mg/day dose after only a 1-week initial treatment with 5 mg/day ARICEPT was higher at 13%.

The most common adverse events leading to discontinuation, defined as those occurring in at least 2% of patients and at twice the incidence seen in placebo patients, are shown in Table 3.

**Table 3 Most Frequent Adverse Events in Patients with Mild to Moderate Alzheimer’s Disease Leading to Withdrawal from Controlled Clinical Trials by Dose Group**

Dose Group	Placebo	5 mg/day ARICEPT	10 mg/day ARICEPT
<b>Number of Patients Randomized</b>	355	350	315
<b>Events/% Discontinuing</b>			
Nausea	1%	1%	3%
Diarrhea	0%	< 1%	3%
Vomiting	< 1%	< 1%	2%

**Most Frequent Adverse Clinical Events Seen in Association with the Use of ARICEPT:** The most common adverse events, defined as those occurring at a frequency of at least 5% in patients receiving 10 mg/day and twice the placebo rate, are largely predicted by ARICEPT’s cholinomimetic effects. These include nausea, diarrhea, insomnia, vomiting, muscle cramp, fatigue and anorexia.

These adverse events were often of mild intensity and transient, resolving during continued ARICEPT treatment without the need for dose modification.

There is evidence to suggest that the frequency of these common adverse events may be affected by the duration of treatment with an initial 5 mg daily dose prior to increasing the dose to 10 mg/day. An open label study was conducted with 269 patients who received placebo in the 15- and 30-week studies. These patients received a 5 mg/day dose for 6 weeks prior to initiating treatment with 10 mg/day. The rates of common adverse events were lower than those seen in controlled clinical trial patients who received 10 mg/day after only a 1-week initial treatment period with a 5 mg daily dose, and were comparable to the rates noted in patients treated only with 5 mg/day.

See Table 4 for a comparison of the most common adverse events following 1- and 6-week initial treatment periods with 5 mg/day ARICEPT.

**Table 4 Comparison of Rates of Adverse Events in Patients with Mild to Moderate Alzheimer’s Disease Treated with 10 mg/day after 1 and 6 Weeks of Initial Treatment with 5 mg/day**

Adverse Event	No Initial treatment		1-Week Initial treatment with 5 mg/day	6-Week Initial treatment with 5 mg/day
	Placebo (N = 315)	5 mg/day (N = 311)	10 mg/day (N = 315)	10 mg/day (N = 269)
Nausea	6%	5%	19%	6%
Diarrhea	5%	8%	15%	9%
Insomnia	6%	6%	14%	6%
Fatigue	3%	4%	8%	3%

Vomiting	3%	3%	8%	5%
Muscle Cramps	2%	6%	8%	3%

Table 5 lists treatment-emergent signs and symptoms (TESS) that were reported in at least 2% of patients from placebo-controlled clinical trials who received ARICEPT and for which the rate of occurrence was greater for ARICEPT than placebo-assigned patients. In general, adverse events occurred more frequently in female patients and with advancing age.

**Table 5 Mild to Moderate Alzheimer’s Disease: Adverse Events Reported in Controlled Clinical Trials in at Least 2% of Patients Receiving ARICEPT and at a Higher Frequency than Placebo-Treated Patients**

<b>Body System/Adverse Events</b>	<b>Placebo n = 355</b>	<b>ARICEPT n = 747</b>
Percent of Patients with any Adverse Event	72	74
<b>Body as a Whole</b>		
Headache	9	10
Pain, various locations	8	9
Accident	6	7
Fatigue	3	5
<b>Cardiovascular System</b>		
Syncope	1	2
<b>Digestive System</b>		
Nausea	6	11
Diarrhea	5	10
Vomiting	3	5
Anorexia	2	4
<b>Hemic and Lymphatic System</b>		
Ecchymosis	3	4
<b>Metabolic and Nutritional</b>		
Weight Decrease	1	3
<b>Musculoskeletal System</b>		
Muscle Cramps	2	6
Arthritis	1	2
<b>Nervous System</b>		
Insomnia	6	9
Dizziness	6	8
Depression	< 1	3
Abnormal Dreams	0	3
Somnolence	< 1	2
<b>Urogenital</b>		
Frequent Urination	1	2

**Long Term Safety:** Patients were exposed to ARICEPT in 2 open-label extension mild to moderate Alzheimer’s disease studies (n = 885) of over 2 years. In 1 of the studies, 763 patients who previously

completed 1 of 2 placebo-controlled studies of 15 or 30 weeks duration continued to receive ARICEPT and were evaluated for safety and neuropsychological evaluations for up to 152 weeks; the safety profile of ARICEPT in this extension study remained consistent with that observed in placebo-controlled trials. Following 1 and 2 years of treatment, 76% (n = 580) and 49% (n = 374) of these patients, respectively, were still receiving therapy (cumulative Weeks 48 and 108).

### **Severe Alzheimer’s Disease**

A total of 573 patients with severe Alzheimer’s disease were treated in controlled clinical studies with ARICEPT. Of these patients, 441 (77%) completed the studies. The duration of double-blind treatment in all studies was 24 weeks. The mean duration of treatment for all ARICEPT groups was 148.4 days (range 1-231 days). The mean daily dose of ARICEPT was 7.5 mg/day.

In clinical trials of patients with severe Alzheimer’s disease, most patients with significant comorbid conditions were excluded. The use of ARICEPT in Alzheimer’s disease patients with chronic illnesses common among the geriatric population, should be considered only after careful risk/benefit assessment and should include close monitoring for adverse events.

**Adverse Events Leading to Discontinuation:** In controlled clinical trials in severe Alzheimer’s disease, the rate of discontinuation due to adverse events was 11.3% in patients treated with ARICEPT compared to 6.7% in the placebo group. The most common adverse events that led to discontinuation, more often in patients treated with ARICEPT than placebo, were diarrhea, nausea, vomiting, urinary tract infection, decreased appetite, and aggression. Each of these adverse events led to discontinuation of less than 2% of patients treated with ARICEPT.

**Most Frequent Adverse Clinical Events Seen in Association with the Use of ARICEPT:** The incidence profile for adverse events for severe Alzheimer’s disease was similar to that of mild to moderate Alzheimer’s disease (see Table 6).

The most common adverse events, defined as those occurring at a frequency of at least 5% in patients and twice the placebo rate, were vomiting, diarrhea, nausea, and aggression. Overall, the majority of adverse events were judged by the investigators to be mild or moderate in intensity.

Table 6 lists treatment-emergent signs and symptoms (TESS) that were reported in at least 2% of patients from placebo-controlled clinical trials who received ARICEPT and for which the rate of occurrence was greater for ARICEPT than placebo-assigned patients.

**Table 6 Severe Alzheimer’s Disease: Adverse Events Reported in Controlled Clinical Trials in at Least 2% of Patients Receiving ARICEPT and at a Higher Frequency than Placebo-Treated Patients**

Body system/Adverse events	Placebo N = 465	ARICEPT N = 573
<b>Percent of Patients with Any Adverse Event</b>	<b>74</b>	<b>81</b>
<b>Gastrointestinal</b>		
Diarrhea	4	10
Vomiting	4	8
Nausea	3	6
Fecal incontinence	1	2

<b>General</b>		
Pyrexia	1	2
Chest pain	0	2
<b>Infections and infestations</b>		
Urinary tract infection	7	8
Nasopharyngitis	6	8
Pneumonia	3	4
<b>Injury, poisoning, procedural complications</b>		
Fall	9	10
Contusion	2	4
Skin laceration	1	2
<b>Investigations</b>		
Blood creatine phosphokinase increased	1	2
<b>Metabolism and nutrition</b>		
Anorexia	2	4
Decreased appetite	1	3
Dehydration	1	2
<b>Musculoskeletal and connective tissue</b>		
Back pain	2	3
Osteoarthritis	1	2
<b>Nervous system</b>		
Headache	3	5
Somnolence	0	2
<b>Psychiatric</b>		
Aggression	2	5
Insomnia	3	4
Restlessness	2	3
Hallucination	1	2
Confusional state	1	2
<b>Renal and urinary</b>		
Urinary incontinence	2	3
<b>Respiratory</b>		
Cough	1	2
<b>Skin</b>		
Eczema	1	2
<b>Vascular</b>		
Hypertension	1	2

A frequency of 0 has been used when frequencies were < 0.5%

Results from the controlled clinical trials indicate that the incidence of adverse events such as vomiting, urinary tract infection, urinary incontinence, pneumonia, falls, decreased appetite, aggression, restlessness, hallucination and confusion may be higher in ARICEPT and placebo-treated patients with severe Alzheimer's disease than in patients with mild to moderate Alzheimer's disease.



Other adverse events that occurred with an incidence of at least 2% in ARICEPT-treated patients and at an equal or lower rate than in placebo treated patients included: abdominal pain, fatigue, gastroenteritis, excoriation, dizziness, anxiety and depression.

**Long Term Safety:** In Study 315, which was a 24 week, randomized, placebo-controlled study in severe Alzheimer's patients, at the end of double-blind treatment 229 patients entered open label ARICEPT treatment for up to an additional 12 weeks. Therefore, at the end of the open label phase, 111 patients had received up to 36 weeks of ARICEPT treatment and 118 patients had received up to 12 weeks of ARICEPT treatment.

The most commonly affected body systems, types and frequencies of adverse events reported during 12 weeks of open label ARICEPT treatment were similar to what was observed during 24 weeks of double-blind treatment.

Gastrointestinal adverse events (diarrhea, nausea, vomiting, anorexia) were reported at a higher frequency in patients who received up to 12 weeks of ARICEPT treatment. Other adverse events reported at higher frequencies in the patients treated with ARICEPT for up to 12 weeks included infection, insomnia, pneumonia, fever, dizziness, hypertension, asthenia, tremor, pharyngitis, hallucinations, convulsions and cysts.

In patients treated with ARICEPT for up to 36 weeks, accidental injury, urinary incontinence and urinary tract infections were reported at higher frequencies.

### **8.3 Less Common Clinical Trial Adverse Reactions**

During the premarketing phase, ARICEPT has been administered to over 1700 individuals with mild to moderate Alzheimer's disease for various lengths of time during clinical trials worldwide. Approximately 1200 patients have been treated for at least 3 months, and more than 1000 patients have been treated for at least 6 months. Controlled and uncontrolled trials in the United States included approximately 900 patients. In regards to the highest dose of 10 mg/day, this population includes 650 patients treated for 3 months, 475 patients treated for 6 months and 115 patients treated for over 1 year. The range of patient exposure is from 1 to 1214 days.

Treatment-emergent signs and symptoms that occurred during 3 placebo-controlled clinical trials and 2 open-label trials of patients with mild to moderate Alzheimer's disease were recorded as adverse events by the clinical investigators using terminology of their own choosing. To provide an overall estimate of the proportion of individuals having similar types of events, the studies were integrated and the events were grouped into a smaller number of standardized categories using a modified COSTART dictionary and event frequencies were calculated across all studies. These categories are used in the listing below. The frequencies represent the proportion of 900 patients from these trials who experienced that event while receiving ARICEPT. All adverse events occurring at least twice are included. Adverse events already listed in Tables 4 and 5 are not repeated here (i.e., events occurring at an incidence > 2%). Also excluded are COSTART terms too general to be informative, or events less likely to be drug-caused. Events are classified by body system and listed as occurring in  $\geq 1\%$  and  $< 2\%$  of patients (i.e., in 1/100 to 2/100 patients: frequent) or in  $< 1\%$  of patients (i.e., in 1/100 to 1/1000 patients: infrequent). These adverse events are not necessarily related to ARICEPT treatment and in most cases were observed at a similar frequency in placebo-treated patients in the controlled studies.

Adverse Events Occurring in  $\geq 1\%$  and  $< 2\%$  or  $< 1\%$  of Patients Receiving ARICEPT:

**Body as a Whole:** ( $\geq 1\%$  and  $< 2\%$ ) influenza, chest pain, toothache; ( $< 1\%$ ) fever, edema face, periorbital edema, hernia hiatal, abscess, cellulitis, chills, generalized coldness, head fullness, head pressure, listlessness.

**Cardiovascular System:** ( $\geq 1\%$  and  $< 2\%$ ) hypertension, vasodilation, atrial fibrillation, hot flashes, hypotension; ( $< 1\%$ ) angina pectoris, postural hypotension, myocardial infarction, premature ventricular contraction, arrhythmia, AV Block (first degree), congestive heart failure, arteritis, bradycardia, peripheral vascular disease, supraventricular tachycardia, deep vein thromboses.

**Digestive System:** ( $\geq 1\%$  and  $< 2\%$ ) fecal incontinence, gastrointestinal bleeding, bloating, epigastric pain; ( $< 1\%$ ) eructation, gingivitis, increased appetite, flatulence, periodontal abscess, cholelithiasis, diverticulitis, drooling, dry mouth, fever sore, gastritis, irritable colon, tongue edema, epigastric distress, gastroenteritis, increased transaminases, hemorrhoids, ileus, increased thirst, jaundice, melena, polydipsia, duodenal ulcer, stomach ulcer.

**Endocrine System:** ( $< 1\%$ ) diabetes mellitus, goiter.

**Hemic & Lymphatic System:** ( $< 1\%$ ) anemia, thrombocythemia, thrombocytopenia, eosinophilia, erythrocytopenia.

**Nutritional Disorders:** ( $\geq 1\%$  and  $< 2\%$ ) dehydration; ( $< 1\%$ ) gout, hypokalemia, increased creatine kinase, hyperglycemia, weight increase, increased lactate dehydrogenase.

**Musculoskeletal System:** ( $\geq 1\%$  and  $< 2\%$ ) bone fracture; ( $< 1\%$ ) muscle weakness, muscle fasciculation.

**Nervous System:** ( $\geq 1\%$  and  $< 2\%$ ) delusions, tremor, irritability, paresthesia, aggression, vertigo, ataxia, libido increased, restlessness, abnormal crying, nervousness, aphasia; ( $< 1\%$ ) cerebrovascular accident, intracranial hemorrhage, transient ischemic attack, emotional lability, neuralgia, coldness (localized), muscle spasm, dysphoria, gait abnormality, hypertonia, hypokinesia, neurodermatitis, numbness (localized), paranoia, dysarthria, dysphasia, hostility, decreased libido, melancholia, emotional withdrawal, nystagmus, pacing, seizures.

**Respiratory System:** ( $\geq 1\%$  and  $< 2\%$ ) dyspnea, sore throat, bronchitis; ( $< 1\%$ ) epistaxis, postnasal drip, pneumonia, hyperventilation, pulmonary congestion, wheezing, hypoxia, pharyngitis, pleurisy, pulmonary collapse, sleep apnea, snoring.

**Skin and Appendages:** ( $\geq 1\%$  and  $< 2\%$ ) abrasion, pruritus, diaphoresis, urticaria; ( $< 1\%$ ) dermatitis, erythema, skin discoloration, hyperkeratosis, alopecia, fungal dermatitis, herpes zoster, hirsutism, skin striae, night sweats, skin ulcer.

**Special Senses:** ( $\geq 1\%$  and  $< 2\%$ ) cataract, eye irritation, blurred vision; ( $< 1\%$ ) dry eyes, glaucoma, earache, tinnitus, blepharitis, decreased hearing, retinal hemorrhage, otitis externa, otitis media, bad taste, conjunctival hemorrhage, ear buzzing, motion sickness, spots before eyes.

**Urogenital System:** ( $\geq 1\%$  and  $< 2\%$ ) urinary incontinence, nocturia; ( $< 1\%$ ) dysuria, hematuria, urinary urgency, metrorrhagia, cystitis, enuresis, prostate hypertrophy, pyelonephritis, inability to empty bladder, breast fibroadenosis, fibrocystic breast, mastitis, pyuria, renal failure, vaginitis.

#### **8.4 Abnormal Laboratory Findings: Hematology, Clinical Chemistry and Other Quantitative Data**

Minor increase in serum concentration of muscle creatine kinase have been reported.

## 8.5 Post-Market Adverse Reactions

Voluntary reports of adverse events temporally associated with ARICEPT that have been received since market introduction that are not listed above, and that for which there is inadequate data to determine the causal relationship with the drug include the following: abdominal pain, agitation, cholecystitis, convulsions, rhabdomyolysis, neuroleptic malignant syndrome (NMS), electrocardiogram QT prolonged, heart block (all types), hemolytic anemia, liver disfunction including hepatitis, hypersexuality, hyponatremia, libido increased, pancreatitis, pleurothotonus (Pisa syndrome), rash, long QT syndrome, torsades de pointes, sudden cardiac death, sudden death, ventricular tachychardia, extrapyramidal symptoms, sino-atrial block, atrioventricular block, common cold, hallucinations, agitation, aggressive behavior, abnormal dreams and nightmares, syncope, seizure, and salivary hypersecretion.

## 9 DRUG INTERACTIONS

### 9.2 Drug Interactions Overview

**Use with Anticholinergics:** Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications.

**Use with Cholinomimetics and Other Cholinesterase Inhibitors:** A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.

**Use with Other Psychoactive Drugs:** Few patients in controlled clinical trials received neuroleptics, antidepressants or anticonvulsants. There is thus limited information concerning the interaction of ARICEPT with these drugs.

**Use with other medicinal products known to prolong the QTc interval:** Caution is advised when donepezil hydrochloride is used in combination with other medicinal products known to prolong the QTc interval and clinical monitoring (ECG) may be required. Examples may include but are not limited to: Class IA antiarrhythmics (e.g. quinidine), Class III antiarrhythmics (e.g. amiodarone, sotalol), certain antidepressants (e.g. citalopram, escitalopram, amitriptyline), other antipsychotics (e.g. phenothiazine derivatives, sertindole, pimozide, ziprasidone), certain antibiotics (e.g. clarithromycin, erythromycin, levofloxacin, moxifloxacin).

### 9.4 Drug-Drug Interactions

Pharmacokinetic studies, limited to short-term, single-dose studies in young subjects evaluated the potential of ARICEPT for interaction with theophylline, cimetidine, warfarin and digoxin administration. No significant effects on the pharmacokinetics of these drugs were observed. Similar studies in elderly patients were not done.

**Drugs Highly Bound to Plasma Proteins:** Drug displacement studies have been performed *in vitro* between donepezil, a highly bound drug (96%) and other drugs such as furosemide, digoxin, and warfarin. Donepezil at concentrations of 0.3 - 10 mg/mL did not affect the binding of furosemide (5 mg/mL), digoxin (2 ng/mL) and warfarin (3 mg/mL) to human albumin. Similarly, the binding of donepezil to human albumin was not affected by furosemide, digoxin and warfarin.

**Effect of ARICEPT on the Metabolism of Other Drugs:** *In vitro* studies show a low rate of donepezil binding to CYP 3A4 and CYP 2D6 isoenzymes (mean  $K_i$  about 50-130 nM), which, given the therapeutic plasma concentrations of donepezil (164 nM), indicates little likelihood of interferences.

In a pharmacokinetic study involving 18 healthy volunteers, the administration of ARICEPT at a dose of 5 mg/day for 7 days had no clinically significant effect on the pharmacokinetics of ketoconazole. No other clinical trials have been conducted to investigate the effect of ARICEPT on the clearance of drugs metabolized by CYP 3A4 (e.g., cisapride, terfenadine) or by CYP 2D6 (e.g., imipramine).

It is not known whether ARICEPT has any potential for enzyme induction.

**Effect of Other Drugs on the Metabolism of ARICEPT:** Ketoconazole and quinidine, inhibitors of CYP450, 3A4 and 2D6, respectively, inhibit donepezil metabolism *in vitro*. In a pharmacokinetic study, 18 healthy volunteers received 5 mg/day ARICEPT together with 200 mg/day ketoconazole for 7 days. In these volunteers, mean donepezil plasma concentrations were increased by about 30%-36%.

Inducers of CYP 2D6 and CYP 3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin and phenobarbital) could increase the rate of elimination of ARICEPT.

Pharmacokinetic studies demonstrated that the metabolism of ARICEPT is not significantly affected by concurrent administration of digoxin or cimetidine.

**Metoclopramide:** Considering the possibility of an additive extra-pyramidal effect the concomitant use of metoclopramide and donepezil hydrochloride is not recommended.

**Beta-blockers:** Additive effects leading to bradycardia (which may result in syncope) have been reported with the combined use of various beta-blockers (including atenolol). Cardio-selective beta-blockers are expected to be associated with the greatest risk, but reports have also been received in patients using other beta-blockers.

## 9.5 Drug-Food Interactions

Food does not have an influence on the rate and extent of donepezil hydrochloride absorption.

## 9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

## 9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

# 10 CLINICAL PHARMACOLOGY

## 10.1 Mechanism of Action

ARICEPT (donepezil hydrochloride) is a piperidine-based, reversible inhibitor of the enzyme acetylcholinesterase (AChE).

A consistent pathological change in Alzheimer's disease is the degeneration of cholinergic neuronal pathways that project from the basal forebrain to the cerebral cortex and hippocampus. The resulting hypofunction of the cholinergic systems is thought to account for some of the clinical manifestations of dementia. Donepezil is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine (ACh) through reversible inhibition of its hydrolysis by AChE.

There is no evidence that donepezil alters the course of the underlying dementing process.

### 10.3 Pharmacokinetics

#### Absorption

Donepezil hydrochloride is well absorbed with a relative oral bioavailability of 100% and reaches peak plasma concentrations ( $C_{max}$ ) approximately 3 to 4 hours after dose administration. Plasma concentrations and area under the curve (AUC) were found to rise in proportion to the dose administered within the 1 to 10 mg dose range studied. The terminal disposition half-life ( $t_{1/2}$ ) is approximately 70 hours and the mean apparent plasma clearance ( $Cl_r/F$ ) is 0.13L/hr/kg. Following multiple dose administration, donepezil hydrochloride accumulates in plasma by 4-7 fold and steady state is reached within 15 days. The minimum, maximum and steady-state plasma concentrations ( $C$ ) and pharmacodynamic effect ( $E$ , percent inhibition of AChE in erythrocyte membranes) of donepezil hydrochloride in healthy adult male and female volunteers are given in Table 7.

**Table 7 Plasma Concentrations and Pharmacodynamic Effect of Donepezil Hydrochloride at Steady-State (Mean  $\pm$  S.D.)**

Dose (mg/day)	$C_{min}$ (ng/mL)	$C_{max}$ (ng/mL)	$C_{ss}^1$ (ng/mL)	$E_{min}$ %	$E_{max}$ %	$E_{ss}^2$ %
5	21.4 $\pm$ 3.8	34.1 $\pm$ 7.3	26.5 $\pm$ 3.9	62.2 $\pm$ 5.8	71.8 $\pm$ 4.3	65.3 $\pm$ 5.2
10	38.5 $\pm$ 8.6	60.5 $\pm$ 10.0	47.0 $\pm$ 8.2	74.7 $\pm$ 4.4	83.6 $\pm$ 1.9	77.8 $\pm$ 3.0

<sup>1</sup>  $C_{ss}$ : Plasma concentration at steady state

<sup>2</sup>  $E_{ss}$ : Inhibition of erythrocyte membrane acetylcholinesterase at steady state

The range of inhibition of erythrocyte membrane AChE noted in Alzheimer's disease patients in controlled clinical trials was 40 to 80% and 60 to 90% for the 5 mg/day and 10 mg/day doses, respectively.

Pharmacokinetic parameters from healthy adult male and female volunteers participating in a multiple-dose study where single daily doses of 5 mg or 10 mg of donepezil hydrochloride were administered each evening are summarized in Table 8. Treatment duration was 1 month. However, volunteers randomized to the 10 mg/day dose group initially received 5 mg daily doses of donepezil hydrochloride for 1 week before receiving the 10 mg daily dose for the next 3 weeks in order to avoid acute cholinergic effects.

**Table 8 Pharmacokinetic Parameters of Donepezil Hydrochloride at Steady-State (Mean  $\pm$  S.D.)**

Dose (mg/day)	$t_{max}$ (hr)	$AUC_{0-24}$ (ng-hr/mL)	$Cl_r/F$ (L/hr/kg)	$V_z/F$ (L/kg)	$t_{1/2}$ (hr)
5	3.0 $\pm$ 1.4	634.8 $\pm$ 92.2	0.110 $\pm$ 0.02	11.8 $\pm$ 1.7	72.7 $\pm$ 10.6
10	3.9 $\pm$ 1.0	1127.8 $\pm$ 195.9	0.110 $\pm$ 0.02	11.6 $\pm$ 1.9	73.5 $\pm$ 11.8

$t_{max}$ : Time to maximal plasma concentration

$AUC_{0-24}$ : Area under the plasma concentration versus time curve from 0 to 24 hours

$Cl_r/F$ : Mean apparent plasma clearance

$V_z/F$ : Apparent volume of distribution

$t_{1/2}$ : Elimination half-life

Neither food nor time of dose administration (i.e., morning versus evening dose) have an influence on the rate and extent of donepezil hydrochloride absorption.

The effect of achlorhydria on the absorption of donepezil hydrochloride is unknown.

**Distribution:**

Donepezil hydrochloride is about 96% bound to human plasma proteins, mainly to albumins (~75%) and a1-acid glycoprotein (~21%) over the concentration range of 2 to 1000 ng/mL.

**Metabolism/Excretion:**

Donepezil hydrochloride is extensively metabolized and is also excreted in the urine as parent drug. The rate of metabolism of donepezil hydrochloride is slow and does not appear to be saturable. There are 4 major metabolites – 2 of which are known to be active - and a number of minor metabolites, not all of which have been identified. Donepezil hydrochloride is metabolized by CYP 450 isoenzymes 2D6 and 3A4 and undergoes glucuronidation. Following administration of a single 5 mg dose of 14C-labelled donepezil hydrochloride, plasma radioactivity, expressed as a percent of the administered dose, was present primarily as unchanged donepezil hydrochloride (53%), and as 6-O-desmethyl donepezil (11%) which has been reported to inhibit AChE to the same extent as donepezil *in vitro* and was found in plasma at concentrations equal to about 20% of donepezil hydrochloride. Approximately 57% of the total administered radioactivity was recovered from the urine and 15% was recovered from the feces (total recovery of 72%) over a period of 10 days. Approximately 28% of the labelled donepezil hydrochloride remained uncovered, with about 17% of the donepezil hydrochloride dose recovered in the urine as parent drug.

**Special Populations and Conditions**

- **Genetic Polymorphism:** No formal pharmacokinetic study was conducted to examine age and gender related differences in the pharmacokinetic profile of donepezil hydrochloride. However, mean plasma donepezil hydrochloride concentrations measured during therapeutic drug monitoring of elderly male and female patients with Alzheimer’s disease are comparable to those observed in young healthy volunteers.
- **Ethnic Origin:** No specific pharmacokinetic study was conducted to investigate the effects of race on the disposition of donepezil hydrochloride. However, retrospective pharmacokinetic analysis indicates that gender and race (Japanese and Caucasians) did not affect the clearance of donepezil hydrochloride.
- **Hepatic Insufficiency:** In a study of 10 patients with stable alcoholic cirrhosis, the clearance of donepezil hydrochloride was decreased by 20% relative to 10 healthy age and sex matched subjects.
- **Renal Insufficiency:** In a study of 4 patients with moderate to severe renal impairment (Clcr <22 mL/min/1.73 m<sup>2</sup>) the clearance of donepezil hydrochloride did not differ from that of 4 age and sex matched healthy subjects.

**11 STORAGE, STABILITY AND DISPOSAL**

ARICEPT tablets should be stored at controlled room temperature, 15°C to 30°C and away from moisture.

Keep out of reach and sight of children.

## PART II: SCIENTIFIC INFORMATION

### 13 PHARMACEUTICAL INFORMATION


#### Drug Substance

Proper name: donepezil hydrochloride

Chemical name: (±)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidiny]methyl]-1H-inden-1-one hydrochloride

Molecular formula and molecular mass: C<sub>24</sub>H<sub>29</sub>NO<sub>3</sub>HCl and 415.96

Structural formula:



Racemic mixture commonly referred to as E2020.

Physicochemical properties: Donepezil hydrochloride is a white crystalline powder

Solubility: Freely soluble in chloroform, soluble in water and in glacial acetic acid, slightly soluble in ethanol and in acetonitrile, and practically insoluble in ethyl acetate and in n-hexane.

## 14 CLINICAL TRIALS

### 14.1 Clinical Trials by Indication

ARICEPT (donepezil hydrochloride) has been studied in three Phase 3 trials in patients with mild to moderate Alzheimer's disease, one Phase 3b trial in patients with moderate to severe Alzheimer's disease, three Phase 3 trials in patients with severe Alzheimer's disease.

#### **Mild to Moderate Alzheimer's Disease:**

##### ***24-Week Trials in Patients with Mild to Moderate Alzheimer's Disease***

Two 24-week studies were conducted in patients with mild to moderate Alzheimer's disease (diagnosed by DSM III-R and NINCDS criteria, Mini-Mental State Examination (MMSE)  $\geq 10$  and  $\leq 26$  as well as a Clinical Dementia Rating of 1 or 2) and provided efficacy and safety data for ARICEPT in this patient population. In these studies, the mean age of patients was 73 years with a range of 50 to 94 years. Approximately 60% of the patients were women and 40% were men. The racial distribution was as follows: white: 97%, black: 2% and other races: 1%.

The primary efficacy of treatment with ARICEPT was evaluated using a dual outcome assessment strategy. The ability of donepezil hydrochloride to improve cognitive performance was assessed with the cognitive sub-scale of the Alzheimer's disease Assessment Scale (ADAS-cog), a widely used and well validated multi-item instrument which samples cognitive domains affected by the disease. The ability of ARICEPT to produce an overall clinical effect was assessed using the semi-structured CIBIC-Plus (Clinician's Interview Based Impression of Change that required the use of caregiver information). The CIBIC-Plus evaluates 4 major areas of functioning: general, cognition, behaviour and activities of daily living. Among the secondary measures of efficacy, the Clinical Dementia Rating Scale - Sum of the Boxes (CDR-SB) or the Interview for Deterioration in Daily Functioning in Dementia (IDDD) were used. The CDR-SB sums the ratings in each of 6 domains ("boxes") of the CDR to provide a clinical measure of global functioning in patients. Information to rate each domain is obtained by semi-structured clinical interviews with both the patients and a caregiver. The IDDD questionnaire evaluates activities of daily living: self-care (e.g., dressing) and complex tasks (e.g., finding things).

The data below summarizes results from two 24-week trials and presents the 2 primary, and the secondary, outcome measures from the Intent-to-Treat population [ITT analysis, i.e., all patients who were randomized to treatment, regardless of whether or not they were able to complete the study. For patients unable to complete the study, their last observation while on treatment was carried forward and used at endpoint (Week 24-LOCF)].


In each of the controlled clinical trials, in order to reduce the likelihood of cholinergic effects, the 10 mg/day treatment group received 5 mg/day for the first week prior to receiving their first 10 mg daily dose.

**Study 302: A 24-Week Study:** In this Phase 3 study, 473 patients were randomized to receive single daily doses of placebo, 5 mg/day or 10 mg/day of ARICEPT for 24 weeks of double-blind active treatment followed by a 6-week single-blind placebo washout period. Patients treated with ARICEPT showed significant improvement in ADAS-cog score from baseline, and when compared with placebo. The mean differences in the ADAS-cog change scores for ARICEPT-treated patients compared to the patients on placebo at Week 24-LOCF were (mean  $\pm$  standard error)  $-2.50 \pm 0.63$  ( $p < 0.0001$ ) and  $-2.87 \pm 0.63$  ( $p < 0.0001$ ) units for the 5 mg/day and 10 mg/day treatments, respectively. Over the 24-week treatment period, 80% (5 mg) and 81% (10 mg) of ARICEPT-treated patients versus 58% placebo treated patients



showed an improvement or no evidence of deterioration (scores  $\geq 0$ ). A score  $\geq 4$  points in ADAS-cog was observed in 38% (5 mg) and 54% (10 mg) of donepezil treated patients versus 27% for placebo. A  $\geq 7$  points improvement was observed in 15% (5 mg) and 25% (10 mg) of donepezil treated patients versus 8% for placebo. The mean drug-placebo differences at Week 24-LOCF in CIBIC Plus scores were  $0.37 \pm 0.12$  ( $p < 0.0047$ ) and  $0.47 \pm 0.11$  ( $p < 0.0001$ ) units for 5 and 10 mg/day of ARICEPT, respectively. Figure 1 represents the frequency distribution of CIBIC Plus scores achieved at Week 24 LOCF by patients assigned to each of the 3 treatment groups.


**Figure 1 Frequency Distribution of CIBIC-Plus Scores at Week 24-LOCF by Patients Assigned to Each Treatment Group**



For the CDR-SB, a secondary efficacy measure, significant drug-placebo differences were observed at Week 24 LOCF for both treatment groups [mean change from placebo: 5 mg =  $0.59 \pm 0.17$  ( $p = 0.0008$ ); 10 mg =  $0.59 \pm 0.17$  ( $p = 0.0007$ )].

**Study 304: A 24-Week Study:** In this Phase 3 multinational study, 818 patients were randomly assigned to treatment with placebo, 5 or 10mg/day of ARICEPT for 24 weeks followed by a 6-week, single-blind placebo washout. ADAS-Cog mean change scores for the ARICEPT- treated patients compared to the patients on placebo at Week 24-LOCF were (mean  $\pm$  standard error)  $-1.55 \pm 0.48$  ( $p = 0.0021$ ) and  $-3.01 \pm 0.49$  ( $p < 0.0001$ ) units for the 5 mg/day and 10 mg/day treatments, respectively. On the CIBIC-Plus, statistically significant mean changes scores were observed in both the ARICEPT 5 mg ( $0.27 \pm 0.09$ ;  $p = 0.0072$ ) and 10 mg/day ( $0.39 \pm 0.10$ ;  $p = 0.0002$ ) at Week 24-LOCF groups in comparison to the placebo-treated group. Figure 2 presents the frequency distribution of CIBIC-Plus scores achieved at Week 24-LOCF by patients assigned to each of the 3 treatment groups.

**Figure 2 Frequency Distribution of CIBIC-Plus Scores Achieved at Week 24-LOCF by Patients Assigned to Each of the 3 Treatment Groups**



With respect to secondary efficacy measures, statistically significant differences over placebo were noted at Week 24-LOCF for both treatment groups in CDR-SB scores [mean change from placebo: 5 mg =  $0.32 \pm 0.14$  ( $p < 0.0033$ ); 10 mg =  $0.42 \pm 0.14$  ( $p < 0.0344$ )] and for the 10 mg ARICEPT group over placebo in the IDDD-complex task measure (mean change from placebo:  $2.15 \pm 0.89$  ( $p = 0.0072$ )).

Following 6 weeks of placebo washout, scores on the ADAS-cog and CIBIC-Plus for both the ARICEPT treatment groups were indistinguishable from those patients who had received only placebo for 30 weeks. This suggests that the beneficial effects of ARICEPT abate over 6 weeks following discontinuation of treatment and therefore represents symptomatic benefits of treatments. There was no evidence of a rebound effect 6 weeks after abrupt discontinuation of therapy. This is in line with the pharmacokinetics of ARICEPT (i.e., ~ 70-hour half-life) which preclude an abrupt reduction in drug plasma levels.

Overall, data from these controlled clinical trials showed that the beneficial symptomatic effects of ARICEPT versus placebo were more consistently apparent after 12 weeks of continuous treatment. Once treatment is discontinued, the effects of ARICEPT were shown to abate within 6 weeks of treatment discontinuation.

**Study 312: 54-Week Trial in Patients with Mild to Moderate Alzheimer’s Disease:** double-blind, placebo-controlled, multicentre 1-year study was conducted in 432 patients with mild to moderate Alzheimer’s disease. The study assessed time to clinically evident loss of function.

Patients were randomized to receive single daily doses of either ARICEPT (n = 214) or placebo (n = 217) for 54 weeks; treatment was initiated at 5 mg/day for 4 weeks, then maintained at 10 mg/day. The mean age of patients was 75 years with a range of 49 to 94 years. 74% of patients were >70 years. Approximately 95% of patients in both treatment groups took at least 1 concomitant medication during the study.


Functional capacities were evaluated using 2 scales: the Alzheimer’s Disease Functional Assessment and Change Scale (ADFACS) scale and the Clinical Dementia Rating (CDR). The ADFACS scale assesses basic activities of daily living (ADL), such as dressing, as well as instrumental ADLs (IADL), such as using the telephone. The CDR assesses cognition and ADLs. Patients were assessed at nine 6-week intervals and

were removed from the study when any of the following 3 criteria were met: 1) decline in ability to perform 1 or more of the ADLs present at baseline; 2) decline in ability to perform 20% or more of IADLs present at baseline; 3) decline in CDR score. The primary outcome was the median time to “clinically evident loss of function” for each arm (Kaplan-Meier Survival Function). The criteria provided a minimum threshold for consideration of withdrawal, with attrition ultimately left to clinical judgement.

The proportion of patients removed was significantly greater for the placebo arm (56%) in comparison to the ARICEPT arm (41%). The median time to loss of clinically evident function in this 1-year study was significantly longer in the ARICEPT-treated patients (357 days) than in the placebo-treated patients (208 days).

Figure 3 below displays the survival curves for time to clinically evident loss of function for both treatment groups. The vertical axis represents the probability of survival to functional decline (in other words, the proportion of individuals remaining in the study at various times following treatment initiation), and the horizontal axis indicates duration of treatment. The 2 survival curves were demonstrated to be significantly different by Wilcoxon and log rank tests, such that the overall risk of clinically evident functional decline for patients treated with ARICEPT was approximately 62% of that of patients who received placebo (hazard ratio 0.62).

**Figure 3 Survival Curves of Time to Clinically Evident Loss of Function for Both Treatment Groups**



**Study 324: A 24-Week Phase 3b Study in Patients with Moderate to Severe Alzheimer’s Disease:** This 24-week, randomized, double-blind, placebo-controlled, multicentre study was conducted in 290 patients with moderate to severe Alzheimer’s disease (MMSE > 5 and < 17; and a Functional Assessment Staging (FAST) score ≤ 6) who resided at home or in an intermediate care-assisted living setting. For 70% of the patients in this study, MMSE scores ranged from ≥ 10 to ≤ 17 and for 62% of patients FAST scores ranged from 4 to 5. According to standard definitions, the MMSE scores for moderate Alzheimer’s disease are ≥ 10 to ≤ 19 and the MMSE score for severe Alzheimer’s disease is ≤ 9. FAST scores for normal aging

to moderate Alzheimer's disease are < 6 and FAST scores for moderately severe to severe Alzheimer's disease are > 6.

Patients were randomized 1:1 to receive either a single daily dose of placebo or ARICEPT for 24 weeks. Patients received 5 mg/day for the first 4 weeks, after which the dose could be increased to 10 mg/day, according to clinical judgement.

The CIBIC-Plus score at the 24-week endpoint was the primary efficacy measure in this study, providing a clinical global assessment of change. For the total patient population, ranging from moderate to severe, statistically significant mean change scores were observed in the ARICEPT-treated patients in comparison to the placebo-treated patients ( $0.538 \pm 0.117$ ;  $p < 0.00001$ ).

### **Severe Alzheimer's Disease**

Three randomized, placebo-controlled 24-week/6-month studies were conducted in 893 patients with severe Alzheimer's disease. In all 3 studies (Study 1017, Study 231, and Study 315) patients were diagnosed with severe Alzheimer's disease according to NINCDS-ADRDA and DSM-IV criteria, MMSE range of 1-10 (Study 1017) or 1-12 (Study 315 and Study 231) and Functional Assessment Staging (FAST) score of 5-7c (Study 1017) or > 6 (Study 231 and Study 315).

**Study Outcome Measures:** The primary efficacy of treatment with ARICEPT was determined using a dual outcome assessment strategy (co-primary efficacy endpoints) that evaluated cognitive function in each of the three trials, and either clinician's global assessment of change (Studies 315 and 231) or activities of daily living through caregiver-related evaluation (Study 1017). A statistically significant treatment difference showing superiority of ARICEPT over placebo ( $p = 0.05$ ) was required for each of the co-primary endpoints for the study outcome to be positive. Based on this criterion, Study 1017 and Study 231 were positive and Study 315 was negative.

The ability of ARICEPT to improve cognitive performance was assessed with the Severe Impairment Battery (SIB). The SIB is a validated and reliable, multi-item instrument that is sensitive to changes in cognitive function in patients with moderate to severe dementia. The SIB evaluates selective aspects of cognitive performance, including elements of memory, language, orientation, attention, praxis, visuospatial ability, construction, and social interaction. The SIB scoring range is from 0 to 100, with lower scores indicating greater cognitive impairment.

Clinician's global assessment of change with ARICEPT treatment was evaluated using the Clinician's Interview Based Impression of Change with caregiver input (CIBIC-Plus) in Study 315 and Study 231. The CIBIC-Plus evaluates 4 major areas of functioning: general, cognition, behaviour and activities of daily living.

Activities of daily living were assessed using the Modified Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory for Severe Alzheimer's Disease (ADCS-ADL-severe). Each ADL item is rated from the highest level of independent performance to complete loss. The ADCS-ADL-severe is a subset of 19 items, including ratings of the patient's ability to perform basic functions (eat, dress, bathe), complex activities (use the telephone, get around (or travel)), and other activities of daily living; it has been validated for the assessment of patients with moderate to severe dementia. The ADCS-ADL-severe has a scoring range of 0 to 54 with the lower scores indicating greater functional impairment.

**Study 1017: A 24-Week Study in Patients with Severe Alzheimer's Disease:** This 6-month, randomized, double-blind, placebo-controlled study was conducted in 248 patients with severe Alzheimer's a skilled nursing home.

Patients were randomized to receive either a single daily dose of ARICEPT or placebo for 24 weeks. For patients randomized to ARICEPT, treatment was initiated at 5 mg/day for 4 weeks, after which the dose was increased to 10 mg/day, based on clinical judgement. The mean age of patients was 84.9 years with a range of 59 to 99. Approximately 77.1% of patients were women and 22.9% were men. The racial distribution was Caucasian: 99.5% and unspecified races: 0.5%.

Co-primary endpoints for this study were the change from baseline to the Month 6 endpoint for the SIB and the ADCS-ADL-severe. Results are presented for the ITT-LOCF analysis.

At the end of the 6-month treatment period, 90.5% of the ARICEPT-treated patients were receiving the 10 mg dose.

Figure 4 shows the time course for the change from baseline in SIB score for the two treatment groups achieved across 6 months. At 6 months LOCF, the mean difference in the SIB change scores for ARICEPT-treated patients compared to placebo-treated patients was 5.7 units. ARICEPT treatment was statistically superior to placebo ( $p = 0.008$ ).

**Figure 4** Time Course of the Change from Baseline in SIB Score Across 24 Weeks





Figure 5 illustrates the time course for the change from baseline in ADCS-ADL-severe scores for patients in the two treatment groups over the 6 months of the study. Although both treatment groups showed a decline in activities of daily living at Week-24 LOCF, the mean difference in the ADCS-ADL-severe change scores for ARICEPT-treated patients compared to patients on placebo was 1.7 units. ARICEPT treatment was statistically superior to placebo ( $p = 0.029$ ).

**Figure 5 Time Course of the Change from Baseline in ADCS-ADL-severe Score Across 24 Weeks**



**Study 231: A 24-Week Study in Patients with Severe Alzheimer’s Disease:** This 24-week, randomized, double-blind, placebo-controlled study was conducted in 302 patients with severe Alzheimer’s disease and required patients to be hospital outpatients or patients attending hospitals via a nursing home. Patients were randomized to receive placebo, ARICEPT low dose or ARICEPT high dose. For the low dose, 3 mg/day were administered for the first 2 weeks, thereafter this was increased to 5 mg/day. For the high dose group, 3 mg/day were administered for the first 2 weeks, then 5 mg/day were administered for 4 weeks and from week 6 onwards, the dose was 10 mg/day. The mean age of patients was 78.2 years with a range of 53 to 98. The racial distribution was Asian: 100%.

Co-primary endpoints for this study were the change from baseline to the Week 24 endpoint on the SIB and the CIBIC-Plus assessment at the Week 24 endpoint. Results are presented for the ITT-LOCF analysis.

The mean difference in SIB change scores at week-24 LOCF for ARICEPT-treated patients compared to patients on placebo was 6.7 units in the ARICEPT 5 mg group and 8.9 units in the ARICEPT 10 mg group. ARICEPT treatment was statistically superior to placebo ( $p < 0.001$ ).

On the CIBIC-Plus, the percentage of patients showing improvement or no change was greater for ARICEPT-treated patients than for patients treated on placebo, while the percentage of patients that worsened was greater for the patients treated on placebo. The difference in the distribution of the scores was statistically significant for the 10 mg group ( $p = 0.003$ ) but not for the 5 mg group ( $p = 0.15$ ).

**Study 315: A 24-Week Study in Patients with Severe Alzheimer’s Disease:** This 24-week randomized, double-blind, placebo-controlled study was conducted in 343 patients with severe Alzheimer’s disease who resided in the community or in an assisted care facility. For patients randomized to ARICEPT, treatment was initiated at 5 mg/day for 6 weeks, after which the dose was increased to 10 mg/day, based on clinical judgement. The mean age of patients was 78.0 years with a range of 58-97. The racial distribution was Caucasian: 76.9%, black: 11.7%, Hispanic: 9.9%, and other races: 1.5%.

Co-primary endpoints for this study were the change from baseline to the Week 24 endpoint on the SIB and the CIBIC-Plus assessment at the Week 24 endpoint. Results are presented for the ITT-LOCF analysis.

At the end of the 24-week treatment period, 86% of the ARICEPT-treated patients were receiving the 10 mg dose.

The mean difference in SIB change scores at week-24 LOCF (5.3 units) indicated that ARICEPT treatment was statistically superior to placebo ( $p = 0.0001$ ).

On the CIBIC-Plus, the difference in the distribution of scores favored ARICEPT (i.e., a greater percentage of patients treated with ARICEPT had improvement or no change and a greater percentage of patients treated with placebo worsened), but the difference was not statistically significant.

## 15 MICROBIOLOGY

No microbiological information is required for this drug product.

## 16 NON-CLINICAL TOXICOLOGY

### PRECLINICAL STUDIES

Preclinical pharmacology studies indicate that donepezil hydrochloride is a reversible inhibitor of AChE *in vitro* exhibiting dose-dependent selectivity for AChE versus BuChE, and that it increases *in vivo* brain concentrations of ACh. In addition, donepezil hydrochloride was shown to improve the performance, in some learning and memory-based tasks, of rodents with pharmacologically- or lesion-induced deficits in brain cholinergic function.

#### General Toxicology:

##### Acute Toxicity Mice and Rats

Acute Oral and IV Bolus Injection Studies in Mice and Rats**			
Route	Species	Sex	LD <sub>50</sub> (mg/kg)
Oral	Mice	M	45.2 *
Oral	Mice	F	48.1 *
Oral	Rats	M	36.9 +
Oral	Rats	F	32.6 +
IV Bolus	Mice	M	3.7 *
IV Bolus	Mice	F	4.8 *
IV Bolus	Rats	M	8.0 +
IV Bolus	Rats	F	7.6 +

Following oral and IV dosing, deaths were recorded at 29.6 mg/kg and higher and 3.5 mg/kg and higher, respectively, in mice, and 28.9 mg/kg and higher and 7.7 mg/kg and higher, respectively, in rats. In mice, all deaths occurred within 30 minutes of oral or IV dosing. The majority of deaths in rats occurred within the first 2 hours after oral administration, although a few were delayed for up to 3 days. The majority of deaths in rats after IV dosing occurred within 30 minutes, although a few were delayed for up to 2 hours. Toxic signs preceding deaths exhibited by both species were: reduced spontaneous movement, prone position, staggering gait, lacrimation (sometimes red in the rat), clonic convulsions, depressed

respiration, and salivation. Toxic signs observed only in rats were: tremors, miosis, and lowered body surface temperature. These signs were also present in the surviving animals at higher doses, and with the exception of clonic convulsions in the rats, were also observed at a lower frequency and intensity in some animals from the lower dose groups. In the surviving mice, all visible toxic signs resolved within 24 hours after dose administration. In the surviving rats, these signs disappeared within 5 days following oral administration and generally disappeared within the first day after IV dosing, although in occasional survivors from the high dose groups signs persisted for up to 3 days.

A significant brief reduction in body weight was noted in the mice during the first few days after dosing of 44.4 mg/kg and 4.6 mg/kg in the oral and IV groups, respectively. In rats, body weight was reduced in all oral administration groups, and in some groups given IV doses of 5.9 mg/kg and higher. Changes in food consumption tended to parallel changes in body weight in mice and rats.

At necropsy, petechial hemorrhages were observed in the lungs of all animals that died in both the oral and intravenous studies. These are consistent with hypoxia due to respiratory paralysis. Petechial hemorrhages were also observed in the glandular mucosa of the stomach in 1 mouse that died after administration of a 150 mg/kg oral dose and in orally treated rats. Aside from the petechiae in the stomach, all the abnormalities observed are consistent with the known effects of ChE inhibitors. In animals that survived the observation period, no pathological changes were observed at necropsy.

**Subacute Toxicity Mice**

SPECIES	ROUTE	DOSE mg/kg/day	ANIMAL PER DOSE LEVEL	DURATION	FINDINGS
<b>2-Week Dietary Administration Study in Mice</b>					
Crj:CD-1	Oral Diet	0 90 180 360	10/sex	2 weeks	Administration of E2020 at doses of 90 and 180 mg/kg did not affect survival. All animals administered 360 mg/kg died before scheduled sacrifice: 2 males and 3 females in the first week, and all remaining animals in that dose group during the second week. Fasciculation was the only clinical sign noted before death.  E2020 administration caused a dose-related and statistically significant depression of body weight at all doses tested. On Day 13, mean body weights in the 90 and 180 mg/kg groups, respectively, were 8% and 31% lower than controls in the males, and 4% and 22% lower than controls in the females. During Week 2, group mean food consumption in the males receiving 90 or 180 mg/kg was 6% and 37% lower than controls, respectively, and was 7% and 39% lower than controls in the females, respectively. Therefore, the depression of body weight was influenced by the decreased food consumption (which may have been due to poor palatability) and was not solely due to E2020 toxicity.



					At necropsy, no abnormalities related to E2020 administration were noted. No NOEL. LOEL = 90 mg/kg/day.
<b>13-Week Dietary Administration Toxicokinetic Study in Mice</b>					
Crl:CD-1 (ICR) BR	Oral Diet	0 15 30 60 90	Main study 10/sex Satellite study 8/sex (controls)  36/sex	13 weeks	E2020 did not affect survival. All abnormalities noted during daily cageside and weekly in-life physical examinations, and grossly at necropsy were incidental findings unrelated to E2020 administration. In males treated with 60 or 90 mg/kg there were statistically significant and dose-dependent increases in absolute and relative weights of the adrenals (organ-to-body and organ-to-brain). However, there was no microscopically detectable cause for the increase in adrenal weights. Statistical analysis of mean absolute body weights revealed significant decreases compared to controls in males treated with 30 mg/kg at Weeks 4 and 5; in males treated with 60 mg/kg at Weeks 2, 4 and 5; in males treated with 90 mg/kg at Weeks 2 through 4; and in females treated with 90 mg/kg at Weeks 2 and 4. However, the mean body weights at Weeks 6 through 13 were not statistically different from controls in any of the E2020-treated groups. NOEL > 30 mg/kg/day MTD > 90 mg/kg/day.

**Subacute Toxicity Rats**

SPECIES	ROUTE	DOSE mg/kg/day	ANIMAL PER DOSE LEVEL	DURATION	FINDINGS
<b>13-Week Study in Rats</b>					
Sprague-Dawley Rats	Oral Gavage	0 10 20  0.3 1 3	20/sex   12/sex	13 weeks	At the end of the 13-week period, 8 of 20 animals per sex from the control, 10 and 20 mg/kg groups were observed without treatment for an additional 5 weeks, and served as recovery groups. Deaths were recorded in 1 male and 3 females from the 20 mg/kg group and in 4 females from the 10 mg/kg group from Day 29 to Day 89. The deaths occurred immediately after dosing except for 1 animal which died 20 minutes postdose.  Peripheral signs of cholinergic stimulation were recorded in animals receiving 3 mg/kg and

				<p>higher. At 3 mg/kg, fasciculation was recorded in 3 rats on separate occasions during the first 8 days, and miosis was noted in 2 animals; these signs resolved within 24 hours of each dose administration. After the eighth day, peripheral signs were no longer present in this group, indicating adaptation to the effects of the drug.</p> <p>Fasciculation, hypoactivity, miosis, salivation and lacrimation were observed in the 10 or 20 mg/kg groups. Except for salivation in the 20 mg/kg group, all of these signs disappeared within 24 hours. In the 10 mg/kg group, miosis and fasciculation became less frequent with continued administration; salivation was more evident in the latter half of the treatment period. Hypoactivity was noted sporadically. No peripheral symptoms were present during the recovery period. Dose-related suppression of body weight gain was recorded in animals receiving 10 or 20 mg/kg. During recovery, body weight gains were greater in the treated animals compared to controls.</p> <p>Sodium excretion in the urine collected 4 to 23 hours postdose was lower in males of all dose groups, and potassium and chloride excretion also decreased in the males receiving 10 mg/kg. Sodium, potassium and chloride excretion were slightly reduced in females receiving 10 or 20 mg/kg. No effects on urinary electrolytes were found at the end of the recovery period.</p> <p><u>Macroscopic postmortem examinations:</u> Moderate mucosal edema of the forestomach in males receiving 10 or 20 mg/kg. An increase in submaxillary gland weight was detected in both sexes receiving 10 or 20 mg/kg; this increase was not present at the end of the recovery period.</p> <p><u>Histopathologic studies:</u> Hypertrophy of the pars intermedia of the pituitary in 7 of 21 animals in the 20 mg/kg group. Acinar cell hypertrophy of the submaxillary gland was recorded in animals receiving 3 mg/kg and higher. A moderate increase in forestomach submucosal edema was found in rats administered 10 or 20 mg/kg. At the end of recovery, no histopathologic changes were found in the pituitary or submaxillary glands;</p>
--	--	--	--	--

					<p>moderate edema of the forestomach was found in 2 rats receiving 10 mg/kg and 1 rat receiving 20 mg/kg.</p> <p>NOEL = 1 mg/kg/day.</p>
--	--	--	--	--	--

**Subacute Toxicity Dogs**

SPECIES	ROUTE	DOSE mg/kg/day	ANIMAL PER DOSE LEVEL	DURATION	FINDINGS
<b>13 Week Study in Dogs</b>					
Beagle Dogs (8 months)	Oral	0 0.3 1 3 8 (reduced to 6 due to high mortality rate)	3/sex/ group	13 weeks	<p>Five deaths were recorded in the 8 mg/kg group. One dog died 7 hours after the first dose and 4 others (including 1 dog killed in extremis) died 3 to 24 hours after the second dose. All these animals exhibited salivation, fasciculation, tremors and convulsions; these signs were evident within 1 hour of dosing except for the convulsions of 1 dog which developed 6 hours after dosing. Muddy or mucous stools were observed in 3 of the dogs from this group, and miosis in 1.</p> <p>From the animals that did not survive to scheduled sacrifice, blood chemistry was available only for the dog killed in extremis. Results showed increased levels of alkaline phosphatase, leucine aminopeptidase, gamma glutamyl transpeptidase, GPT (ALT), GOT (AST), CK, LDH, total bilirubin, urea nitrogen, and a decreased level of glucose. Most of these abnormalities were consistent with skeletal muscle damage secondary to fasciculation, tremors and convulsions. No significant histopathologic changes were noted in the liver. Slight calcium deposition in the papillae and slight necrosis of the distal tubular epithelium were the only notable histopathologic changes in the kidney.</p> <p>Microscopic examination showed subendocardial hemorrhage and myo-fibrillary degeneration in the left ventricular wall, papillary muscle and septum. These findings were due to acute hypoxia, ischemia from respiratory depression and/or catecholamine release caused by fasciculation, tremors and convulsions. Thus, the clinical signs and</p>

				<p>laboratory findings were consistent with excessive acetylcholinesterase inhibition as the cause of death.</p> <p>All remaining animals survived the full study period. Peripheral signs of tremors and fasciculation were observed at doses of 3 mg/kg and higher in these animals. The signs appeared shortly after dosing and resolved within 24 hours. Other signs observed included mucous stools, found sporadically in dogs treated with 3 mg/kg, and miosis was observed on 3 occasions during the first 7 days in 1 dog receiving 3 mg/kg. Incidence of these signs was greatly reduced by the third week of administration, suggesting adaptation to the peripheral effects of donepezil hydrochloride. Body weight and food consumption were unaffected.</p> <p>Ophthalmological examinations, electrocardiograms, hematological and blood chemical investigations and urinalysis showed no abnormalities attributable to donepezil hydrochloride. Drug metabolizing enzymes were also unaffected.</p> <p>There were no significant macroscopic findings at postmortem examination, and no microscopic abnormalities attributable to donepezil hydrochloride. Unlike the animals that died, no significant histopathologic abnormalities were observed in the hearts of dogs that survived the first two 8 mg/kg doses and were reassigned to receive 3 or 6 mg/kg for the remainder of the study.</p> <p>Aside from a few biochemical abnormalities encountered in the 1 female killed in extremis, all abnormal findings are consistent with expected effects of cholinesterase inhibitor treatment. The oral no-effect dose of donepezil hydrochloride was 1 mg/kg/day in dogs.</p>
--	--	--	--	---

**Long Term Rats**

SPECIES	ROUTE	DOSE mg/kg/day	ANIMAL PER DOSE LEVEL	DURATION	FINDINGS
<b>12-Month Study in Rats</b>					
Charles River CD7® Rats	Oral Gavage	0 1.0 3.0 10	40/sex	12 months	<p><u>Mortality:</u> Twenty males and 10 females died spontaneously or were killed by accident, or were sacrificed moribund. These deaths did not indicate a compound-related effect since the deaths were evenly distributed among the groups.</p> <p>Miosis was observed in all treated groups. The incidence of salivation was slightly higher in high-dose animals (10 mg/kg) in the first 30 weeks of dosing. Fasciculations were observed in high-dose females, but this effect was no longer apparent at the end of the 12-month dosing period.</p> <p>There was a treatment-related decrease in body weight in the high-dose group. In the 10 mg/kg group, beginning at Week 7 for males and Week 17 for females, mean body weights were lower than controls. The decrease at Week 53 was 11% for males and 15% for females. Based on this observation, the no-toxic-effect dose of donepezil hydrochloride in this study was 3.0 mg/kg/day.</p> <p><u>Urinalysis:</u> Occasional effects on the diurnal pattern of electrolyte excretion were observed. However, 24-hour urinary electrolyte excretion at 6 and 12 months showed no evidence of drug effects.</p> <p><u>Histopathology:</u> Gross postmortem examinations revealed no indication of treatment-related changes. There was a statistically significant increase in salivary gland weights in high-dose rats at Month 6 and 12, however, no changes were noted in salivary glands on histopathologic evaluation. There were differences between treated and controls in absolute organ and body weights and organ/body weight ratios, but these changes were consistent with body weight changes, and are not believed to be effects of cholinesterase inhibition.</p>

					Based on the significant decrease in body weight in the high-dose group, the no-toxic-effect dose of donepezil hydrochloride administered orally for 12 months was 3.0 mg/kg/day in this study.
--	--	--	--	--	---

**Long Term Dogs**

SPECIES	ROUTE	DOSE mg/kg/day	ANIMAL PER DOSE LEVEL	DURATION	FINDINGS
<b>12-Month Study in Beagle Dogs</b>					
Beagle Dogs	Oral	0 0.6 2.0 5.0	6/sex/ group	2/sex for 6 months  4/sex for 12 months	<p><u>Mortality:</u> One control female died of non-treatment related causes on Day 11 of the study, all other animals survived until scheduled sacrifice. Treatment-related salivation was seen in all groups. Lacrimation (more common in males), tremors and/or hyperactivity (more common in females) were seen in the mid- and high-dose groups. Hyperactivity was also occasionally observed in the low-dose group.</p> <p>Food consumption in high-dose animals was significantly lower than controls during Week 1. There were no other statistically significant effects on food consumption in any group for the remainder of the study.</p> <p>Water consumption was lower in high-dose dogs than controls at the pretest evaluation and at all evaluation intervals during the study. In high-dose females, the differences in water consumption from controls were comparable during pretest and treatment. In high-dose males, water consumption during treatment was 39% to 46% lower than controls, as opposed to 21% lower during pretest, and the differences were statistically significant at Months 3 and 6, but not at Months 9 or 12. This suggests that 5.0 mg/kg/day doses of donepezil hydrochloride have an effect on water consumption in male dogs.</p> <p><u>Urinalysis:</u> Urine volumes and total urine electrolyte values for mid- and high-dose male dogs and high-dose females were lower than controls at most of the evaluation intervals of the study, suggesting an effect of donepezil hydrochloride on urine volume and electrolytes.</p> <p><u>Histopathology:</u> There were few hematologic and biochemistry parameters in the treatment groups that</p>

					<p>were statistically significantly different from control values. The differences seen were not consistently altered, were within the limits of normal variation, and were not considered to represent effects of donepezil hydrochloride administration.</p> <p>The no-toxic-effect dose in this study was 5.0 mg/kg/day.</p>
--	--	--	--	--	---

### Genotoxicity

STUDY	TEST ORGANISM	DOSE	ROUTE	MAJOR FINDINGS
Ames Test  Modified Ames Test:	<i>Salmonella typhimurium</i> strains TA1535, TA1537, TA98 and TA100  <i>E. Coli</i> WP2/uvrA	up to 500 mmg/plate  > 500 mg/plate	<i>in vitro</i>  <i>in vitro</i>	No evidence of mutagenic activity.  Not mutagenic, however suppressed growth of all bacterial strains.
Clastogenic Potential Cytogenetic Assays: <i>in vitro</i> Chromosome Aberration Assay:	Chinese Hamster Lung (CHL) fibroblasts with and without metabolic activation	Non-activation: 3.1 - 50 mg/mL With activation: 11.3 - 270 mg/mL	<i>in vitro</i>  <i>in vitro</i>	No chromosomal aberration produced.  No chromosomal aberration produced up to and including 90 mg/mL. At concentrations of 180 and 270 mg/mL, incidence of chromosomal aberration increased in a dose-related manner in the presence of S-9 mix. In the absence of S-9 mix the incidence of chromosomal aberrations was increased at 180 mg/mL, but cell toxicity precluded evaluation at 270 mg/mL indicating that S-9 protected the cells.
Micronucleus Test:	Mice (Crj: -CD-1 ICR)	2.5 mg/kg 5.0 mg/kg 10 mg/kg single or repeated (4 days)	oral gavage	No evidence of clastogenicity in this <i>in vivo</i> model system. The incidences of cells with micronuclei in both the single and repeated dose groups were not significantly

		(based on study where 20 or 40 mg/kg caused death)		different from those of the vehicle control group.
--	--	--	--	--

### Carcinogenicity

Full-life carcinogenicity studies of donepezil hydrochloride have been completed in mice and rats. No evidence of a tumorigenic effect was seen when donepezil hydrochloride was given in feed to mice for at least 88 weeks at doses up to 180 mg/kg/day, or to rats for at least 104 weeks at doses up to 30 mg/kg/day.

### Reproductive and Developmental Toxicology

SPECIES	ROUTE	DOSE mg/kg/day	ANIMAL PER DOSE LEVEL	DURATION	FINDINGS
<b>Segment II Teratology and Reproduction Study in Rats</b>					
Rat (S1c:SD SPF)	Oral Gavage	0 1 4 16	36F	4 groups of mated females, 36 dams per group; doses from day 7-17 of gestation which correspond to the period of fetal organogenesis	<p><b>Dams:</b> At 4 and 16 mg/kg/day, 2 hours after dosing miosis, mean weight body weight gain and food consumption were significantly lower than controls. Following the 16-mg dose, fasciculations, lacrimation and salivation. Decreased placental weight; clinical signs ceased from Day 18 onwards; no mortality.</p> <p><b>Fetuses and Pups:</b> At 16 mg/kg/day, live fetuses body weights were significantly lower than controls. No effect on survival or sex ratio of the fetuses. No evidence of teratogenic effect. However, ventricular septal defects were noted in the following number of pups per group: 1 (control group); 0 (1 mg/kg); 1 (4 mg/kg) and 5 (16 mg/kg). One stillborn pup from a dam who received 4 mg/kg donepezil showed several defects, including a ventricular septal defect.</p> <p>Effects on pups after drug exposure during the last third period of gestation or during the beginning of extra-uterine life were not evaluated.</p> <p>No effect dose: Maternal toxicity: 1 mg/kg/day Reproduction: 4 mg/kg/day dams 4 mg/kg/day fetuses &gt;16 mg/kg/day pups</p>



SPECIES	ROUTE	DOSE mg/kg/day	ANIMAL PER DOSE LEVEL	DURATION	FINDINGS
<b>Segment II Teratology Study in Rabbits</b>					
Japanese SPF white rabbits	Oral Gavage	0 1 3 10	16F	4 groups of 16 females per group; doses from day 6 - 18 of gestation which correspond to the period of fetal organogenesis	<p><b>Dams:</b> One dam in the 10 mg/kg/day group was sacrificed in extremis on Day 16 because of a dislocated lumbar vertebra. At 10 mg/kg/day, suppression of body weight gain followed by a significant increase in body weight gain from days 20-28, after cessation of drug. A significant decrease in food consumption was observed on Days 8 and 10. Treatment with donepezil hydrochloride had no effect on the number of corpora lutea, implantations, deaths or resorptions of fetuses, or on the number of live fetuses. No findings at necropsy attributable to study drug; no mortality.</p> <p><b>Fetuses:</b> Donepezil hydrochloride had no effect on uterine survival, growth or development. No evidence of teratogenicity or embryotoxicity. In the 3 mg/kg/day group, incidence of fetuses in which a variant arteriole arose from the bifurcation site of the left common carotid artery and the brachiocephalic trunk was significantly higher than in the controls. In the 10 mg/kg/day group, the number of ossified sternbrae was significantly higher than controls, but no significant differences were noted between controls and any treated group in the numbers of ossified phalanges, or sacral or caudal vertebrae.</p> <p>No effect dose: Maternal toxicity: 3 mg/kg/day Reproduction: 10 mg/kg/day fetuses</p>

## Special Toxicology

### 7-Week Physical Dependence Study in Male Rats

Dependence liability of donepezil hydrochloride was examined in male rats and was compared to the liability of codeine, phenobarbital and vehicle (water).

Dosing in the E-2020-L group began at 6 mg/kg twice daily (BID) and increased each week by 3 mg/kg until the final dose of 18 mg/kg BID was reached. Donepezil hydrochloride-H animals were started at 10

mg/kg BID, and doses were increased by 4 mg/kg each week to a final dose of 26 mg/kg BID. Codeine was started at 10 mg/kg BID, and was increased by 10 mg/kg each week to a final dose of 50 mg/kg BID. Phenobarbital was started at 15 mg/kg BID and was increased by 15 mg/kg each week to a final dose of 75 mg/kg BID.

Results of the observation periods following dose cessation did not suggest any significant drug dependence liability for donepezil hydrochloride. Donepezil hydrochloride did not substitute for codeine or phenobarbital in rats dependent on those drugs. Under the conditions of this study, donepezil hydrochloride did not produce drug dependence.

There were no significant drug dependence liability as assessed by the primary dependence test, donepezil hydrochloride substitution test and naloxone test.

## **PATIENT MEDICATION INFORMATION**

### **READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE**

#### **ARICEPT®**

#### **donepezil hydrochloride tablets**

Read this carefully before you start taking **ARICEPT** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **ARICEPT**.

#### **What is ARICEPT used for?**

ARICEPT is used in adults to treat the symptoms of mild, moderate and severe dementia due to Alzheimer's disease.

#### **How does ARICEPT work?**

People with Alzheimer's disease have a low amount of a chemical called acetylcholine in their brain. It is a substance that is thought to be necessary for memory and other mental functions. ARICEPT helps to stop the breakdown of acetylcholine, which helps to increase the amount of acetylcholine in the brain. This may help relieve the symptoms of dementia related to Alzheimer's disease. It is important to remember that ARICEPT treats the symptoms, it does not cure the disease.

#### **What are the ingredients in ARICEPT?**

Medicinal ingredient: donepezil hydrochloride

Non-medicinal ingredients: corn starch, hydroxypropylcellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide. The 10 mg tablets also contain yellow iron oxide.

#### **ARICEPT comes in the following dosage forms:**

Tablets: 5 mg, 10 mg.

#### **Do not use ARICEPT if:**

- you are allergic to donepezil hydrochloride, or to any of the other ingredients in ARICEPT (see the section "What are the ingredients in ARICEPT?")
- you are allergic to piperidine derivatives such as rifabutin, methylphenidate, biperiden hydrochloride, trihexyphenidyl, bupivacaine, or paroxetine hydrochloride.
- you have a history of heart problems, including heart rhythm problems.

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take ARICEPT. Talk about any health conditions or problems you may have, including if you:**

- have a condition called ‘sick sinus syndrome’ or other heart rhythm disorders.
- have a condition that affects your heart and/or blood vessels such as coronary artery disease, congestive heart failure or a recent heart attack.
- have a history of muscle disorders, including any involuntary movements of the body, face, or limbs.
- have or have had any liver or kidney problems.
- have a condition that affects your lungs, such as asthma or obstructive pulmonary disease.
- have had seizures.
- have had fainting spells.
- have a history of peptic ulcers or have an increased risk of developing ulcers – for example, if you are taking non-steroidal anti-inflammatory drugs (NSAIDs) or high doses of acetylsalicylic acid (ASA, commonly known as Aspirin®).
- need an operation with a general anesthetic; tell your healthcare professional you are taking ARICEPT.
- have hypothyroidism (low levels of thyroid hormone), but are not receiving treatment for it.
- have any of the following rare hereditary problems, because ARICEPT contains lactose:
  - galactose intolerance.
  - Lapp lactase deficiency.
  - glucose-galactose malabsorption.
- are pregnant, think you might be pregnant, or plan to become pregnant.
- are breastfeeding, or plan to breastfeed.
- are elderly (85 years of age or older) and have a low body weight.

**Other warnings you should know about:**

**Muscle problems:** If you experience any muscle pain, tenderness, or weakness and darkened urine, accompanied by a fever or a feeling of being unwell, tell your healthcare professional **right away**.

**Driving and using machines:** ARICEPT may cause you to feel dizzy or drowsy, especially when you first start taking it, or change your dose. If you feel dizzy or drowsy, do not drive, use machines or perform any other tasks that require your attention. Your healthcare professional will tell you if you can drive or use machines.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

**The following may interact with ARICEPT:**

- other medicines like ARICEPT, used to treat symptoms of Alzheimer’s disease.
- medicines known as ‘anticholinergics’ (used to stop the action of a chemical in the brain called acetylcholine).
- medicines known as ‘neuromuscular blocking agents’, such as succinylcholine (used as a muscle relaxant).
- medicines known as ‘cholinergic agonists’, such as bethanechol (used to stimulate the bladder).

- medicines used to treat heart rhythm disorders, such as quinidine, amiodarone, sotalol.
- medicines used to treat depression, such as citalopram, escitalopram, amitriptyline.
- medicines used to treat psychosis, such as phenothiazine, sertindole, pimozide, ziprasidone.
- certain antibiotics, such as clarithromycin, erythromycin, levofloxacin, moxifloxacin, rifampin.
- ketoconazole, used to treat fungal infections.
- medicines used to treat seizure disorders, such as phenytoin, carbamazepine, phenobarbital.
- dexamethasone, used to treat inflammation.
- metoclopramide, used to treat stomach and esophageal problems.
- medicines known as ‘beta-blockers’, used to treat abnormal heart rhythms.

**How to take ARICEPT:**

- Take ARICEPT exactly as your healthcare professional tells you to.
- Swallow tablets whole, with water.
- ARICEPT can be taken with or without food.
- Taking ARICEPT at the same time each day will help you remember when to take your medicine.
- If you experience sleep disturbances such as abnormal dreams, nightmares or insomnia, tell your healthcare professional. They may advise you to take ARICEPT in the morning.

**Usual Dose:**

The recommended starting dose is 5 mg once daily in the morning or evening. Depending on your response to ARICEPT, your healthcare professional may increase your dose. The maximum recommended dose is 10 mg once daily.

**Overdose:**

If you think you, or a person you are caring for, have taken too much ARICEPT, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada’s toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no symptoms.

**Missed Dose:**

If you miss taking a dose of ARICEPT, skip the missed dose and take the next dose at the regular scheduled time. If you have missed your dose for several days or more, tell your healthcare professional, they will tell you how to restart your treatment.

**What are possible side effects from using ARICEPT?**

These are not all the possible side effects you may have when taking ARICEPT. If you experience any side effects not listed here, tell your healthcare professional.

Side effects may include:

- insomnia (difficulty sleeping)
- abnormal dreams
- vomiting (being sick)
- nausea
- diarrhea
- muscle cramps
- fatigue
- anorexia (loss of appetite)
- weight loss
- fever
- headache
- dizziness
- body pain
- accidental falls
- bruising, cuts
- frequent urination
- urinary tract infection (UTI)
- aggression
- restlessness
- hallucinations
- too much saliva

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<b>UNCOMMON</b>			
<b>Anemia</b> (decreased number of red blood cells): fatigue, loss of energy, looking pale, weakness, shortness of breath		√	
<b>Depression</b> (sad mood that won't go away): difficulty sleeping or sleeping too much, changes in appetite or weight, feelings of worthlessness, guilt, regret, helplessness or hopelessness, withdrawal from social situations, family, gatherings and activities with friends, reduced libido (sex		√	

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
drive) and thoughts of death or suicide			
Fainting		√	
<b>Heart Problems</b> (problems affecting your heart muscle, valves or rhythm): chest pain or discomfort, high blood pressure, irregular, fast or slow heart rhythm, shortness of breath, dizziness, fainting			√
<b>Seizures</b> (fits or convulsions)			√
<b>Stomach ulcer and gastrointestinal bleeding:</b> blood in the stools, black, tarry stools or vomiting blood			√
<b>RARE</b>			
<b>Rhabdomyolysis</b> (breakdown of damaged muscle): combination of muscle pain, tenderness, or weakness, or joint pain accompanied by a fever or very dark urine that you cannot explain		√	
<b>VERY RARE</b>			
<b>Neuroleptic Malignant Syndrome:</b> high fever, pronounced muscle stiffness or inflexibility, rapid or irregular heartbeat, sweating, state of confusion or reduced consciousness			√
<b>FREQUENCY UNKNOWN</b>			
<b>Extrapyramidal symptoms:</b> problems controlling movements of the body or limbs, including, but not limited to, stiff limbs, trembling hands, body spasms, upward eye rolling, exaggeration of reflexes, drooling, difficulty moving how and when you want			√
Libido increased, hypersexuality		√	
<b>Liver disorder:</b> yellowing of skin and the whites of eyes, darkening of the urine, unexplained nausea,			√

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
vomiting, loss of appetite, itching, upper stomach pain, tiredness			
<b>Pancreatitis</b> (inflammation of the pancreas): upper abdominal pain, fever, rapid heartbeat, nausea, vomiting, tenderness when touching the abdomen			√
<b>Pisa Syndrome</b> (a neurological condition): involuntary muscle contraction with abnormal bending of the body and head to one side		√	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

#### Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

#### Storage:

Keep ARICEPT tablets in a cool dry place (15 to 30°C) and avoid exposure to moisture.

Keep out of reach and sight of children.

#### If you want more information about ARICEPT:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website [www.pfizer.ca](http://www.pfizer.ca), or by calling 1-800-463-6001



(Medical Information)

This leaflet was prepared by Pfizer Canada ULC.

Last Revised DEC 05, 2024